RECEIVED CENTRAL FAX CENTER

DEC 0 5 2006

PATENT

Attorney Docket No.: 10308.200-US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Draborg et al.

Confirmation No: 6155

Serial No.: 10/699,394

Group Art Unit: 1656

Filed: October 31, 2003

Examiner: W. Moore

For: Subtilase Variants

CERTIFICATE OF FACSIMILE TRANSMISSION

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

I hereby certify that the attached correspondence comprising:

- 1. Amendment Fee Transmittal (in duplicate)
- 2. Amendment
- 3. Notice of Appeal (in duplicate)

was sent to the United States Patent and Trademark Office by telefax to the attention of Examiner W. Moore, fax number (571) 273-8300.

Respectfully submitted,

Date: December 5, 2006

Lourdes Avala

Novozymes North America, Inc. 500 Fifth Avenue, Suite 1600

New York, NY 10110

(212) 840-0097

Attorney Docket No.: 10308.200-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Draborg et al.

Confirmation No: 6155

Serial No.: 10/699,394

Group Art Unit: 1656

RECEIVED CENTRAL FAX CENTER

Filed: October 31, 2003

Examiner: W. Moore

DEC 0 5 2006

For: Subtilase Variants

AMENDMENT FEE TRANSMITTAL

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir.

Transmitted herewith is an Amendment for the above-identified application in response to the Office Action mailed June 16, 2006.

It is respectfully requested that the time for response to the Office Action be extended for a period of 3 months from September 16, 2006 to December 16, 2006. The required fee for the extension is estimated to be \$1,020.

The fee for claims has been calculated as shown below:

Total: $40 - 39 = 1 \times 50 = 50

Independent: $2 - 3 = 0 \times 200 = 0

Total additional fee for claims required is \$50.

Please charge the required extension and claims fees, estimated to be \$1,070, to Novozymes North America, Inc., Deposit Account No. 50-1701. A duplicate of this sheet is enclosed.

Respectfully submitted,

Date: December 5, 2006

Michael W. Krenicky, Reg. No. 45,411 Novozymes North America, Inc.

500 Fifth Avenue, Suite 1600

New York, NY 10110

(212) 840-0097

RECEIVED **CENTRAL FAX CENTER**

DEC 0 5 2006

Attorney Docket No.: 10308-200-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Draborg et al.

Confirmation No: 6155

Serial No.: 10/699,394

Group Art Unit: 1656

Filed: October 31, 2003

Examiner: W. Moore

For: Subtilase Variants

AMENDMENT UNDER 37 C.F.R. 1.116

Mail Stop AF **Commissioner for Patents** P.O. Box 1450 Alexandria, VA 22313-1450

Sir.

In response to the Final Office Action mailed June 16, 2006 please enter the following remarks as follows:

Status of the claims are reflected in the listing of claims, which begins on page 2 of this document.

Remarks and arguments begin on page 16 of this document.

12/07/2006 AWONDAF1 00000083 501701 10699394

01 FC:1202 02 FC:1253

1020.00 DA